BioNxt Solutions Inc.
BNXT
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -30.40% | -89.14% | -92.83% | -89.29% | -92.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.40% | -89.14% | -92.83% | -89.29% | -92.82% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -30.40% | -89.14% | -92.83% | -83.03% | 113.43% |
| SG&A Expenses | 42.26% | -9.12% | -26.84% | -26.02% | -35.07% |
| Depreciation & Amortization | -66.54% | -63.59% | -53.79% | -45.18% | -26.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.42% | -27.35% | -34.33% | -20.06% | -30.29% |
| Operating Income | -0.60% | 25.34% | 30.90% | 15.79% | 26.44% |
| Income Before Tax | 7.52% | 28.15% | 31.03% | 50.83% | 53.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.87% | 29.26% | 32.15% | 48.92% | 51.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.87% | 29.26% | 32.15% | 48.92% | 51.37% |
| EBIT | -0.60% | 25.34% | 30.90% | 15.79% | 26.44% |
| EBITDA | -1.29% | 25.10% | 30.52% | 14.95% | 26.48% |
| EPS Basic | 16.22% | 35.88% | 39.20% | 55.92% | 57.83% |
| Normalized Basic EPS | 12.36% | 33.43% | 35.36% | 25.93% | 32.75% |
| EPS Diluted | 16.22% | 35.88% | 39.20% | 55.92% | 57.83% |
| Normalized Diluted EPS | 12.36% | 33.43% | 35.36% | 25.93% | 32.75% |
| Average Basic Shares Outstanding | 8.21% | 9.66% | 12.30% | 14.45% | 15.74% |
| Average Diluted Shares Outstanding | 8.21% | 9.66% | 12.30% | 14.45% | 15.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |